Wegovy can Potentially Reduce the Risk of Heart-related Deaths
MedEsthetics
SEPTEMBER 28, 2023
The topline results from a select cardiovascular outcomes trial shared by Novo Nordisk found that once-weekly semaglutide 2.4 mg reduced the risk of heart attack, stroke or heart-related deaths by 20%.
Let's personalize your content